Catalyst Wire Dossier Catalyst Wire Dossier

Oral contraceptive (28-day regimen) studied by Teva Branded Pharmaceutical Products R&D, Inc.

· Teva Branded Pharmaceutical Products R&D, Inc.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Oral contraceptive (28-day regimen) studied by Teva Branded Pharmaceutical Products R&D, Inc., covering 2013-11-27 to 2013-11-27. Get the full timeline:

Most recent: Clinical Trial Update: A Multinational Study to Evaluate the Effects of a 28-Day Oral Contraceptive on Hemostatic Parameters in Healthy Women [Phase 2]

See pricing